Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports

Diane Slats; Petra E Spies; Magnus J C Sjögren; Frans R J Verhey; Marcel M Verbeek; Marcel G M Olde Rikkert

doi:10.1159/000286280

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports

Diane Slats, Petra E Spies, Magnus J C Sjögren, Frans R J Verhey, Marcel M Verbeek, Marcel G M Olde Rikkert

2 Citations (Scopus)

Abstract

Analysis of the brain specific biomarkers amyloid beta(42) (Abeta(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.

Original language	English
Book series	Case Reports in Neurology
Volume	2
Issue number	1
Pages (from-to)	5-11
Number of pages	7
ISSN	1662-680X
DOIs	https://doi.org/10.1159/000286280
Publication status	Published - 24 Feb 2010
Externally published	Yes

Access to Document

10.1159/000286280

Cite this

@article{b62607856045452382a945f5b6950f07,

title = "Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports",

abstract = "Analysis of the brain specific biomarkers amyloid beta(42) (Abeta(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85\% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.",

author = "Diane Slats and Spies, \{Petra E\} and Sj{\"o}gren, \{Magnus J C\} and Verhey, \{Frans R J\} and Verbeek, \{Marcel M\} and \{Olde Rikkert\}, \{Marcel G M\}",

year = "2010",

month = feb,

day = "24",

doi = "10.1159/000286280",

language = "English",

volume = "2",

pages = "5--11",

journal = "Case Reports in Neurology",

issn = "1662-680X",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice

T2 - An Illustration with 3 Case Reports

AU - Slats, Diane

AU - Spies, Petra E

AU - Sjögren, Magnus J C

AU - Verhey, Frans R J

AU - Verbeek, Marcel M

AU - Olde Rikkert, Marcel G M

PY - 2010/2/24

Y1 - 2010/2/24

N2 - Analysis of the brain specific biomarkers amyloid beta(42) (Abeta(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.

AB - Analysis of the brain specific biomarkers amyloid beta(42) (Abeta(42)) and total tau (t-tau) protein in cerebrospinal fluid (CSF) has a sensitivity and specificity of more than 85% for differentiating Alzheimer's Disease (AD) from non-demented controls. International guidelines are contradictory in their advice on the use of CSF biomarkers in AD diagnostics, resulting in a lack of consistency in clinical practice. We present three case reports that illustrate clinical practice according to the Dutch and European guidelines and portray the value of CSF biomarker analysis as an add-on diagnostic to the standard diagnostic workup for AD.

UR - https://www.scopus.com/pages/publications/78650686124

U2 - 10.1159/000286280

DO - 10.1159/000286280

M3 - Journal article

C2 - 20689628

SN - 1662-680X

VL - 2

SP - 5

EP - 11

JO - Case Reports in Neurology

JF - Case Reports in Neurology

IS - 1

ER -

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports

Abstract

Access to Document

Other files and links

Fingerprint

Cite this